000 02119cam  2200301za 4500
0019.849043
003CaOODSP
00520221107153825
007cr |||||||||||
008171219s2017    onca|  #o    f000 0 eng d
040 |aCaOODSP|beng
043 |an-cn---
0861 |aH82-30/2017E-PDF
24500|aPMPRB guidelines scoping paper |h[electronic resource] : |bhigh level overview of potential new framework : CGI consultation phase.
24637|aPMPRB potential new guidelines |bhigh level overview of potential new framework - CGI consultation phase
260 |a[Ottawa] : |bPatented Medicine Prices Review Board, |c[2017]
300 |a9 p. : |bcol. ill.
500 |aCover title.
500 |a"This consultation period is 6 weeks, running from May 16, 2017 to June 28, 2017"--p. 5.
500 |aIssued also in French under title: Protéger les Canadiens des prix excessifs des médicaments : consultation sur les modificaations proposées au Règlement sur les médicaments brevetés.
504 |aIncludes bibliographical references.
5200 |a"This scoping paper is intended to be read in conjunction with proposed amendments to the Patented Medicines Regulations (“Regulations”), and accompanying Regulatory Impact Analysis Statement (RIAS), which were pre-published in the December 2nd, 2017 issue of the Canada Gazette, Part I. Its purpose is to provide stakeholders and interested members of the public with an outline of the PMPRB’s preliminary thoughts on how best to operationalize the proposed changes to the Regulations, through non-binding Guidelines as contemplated by s.96 of the Patent Act, within the context of the existing and proposed legislation and the PMPRB’s ongoing efforts at reform"--p. 3 Introd.
69207|2gccst|aDrugs
69207|2gccst|aPrice regulation
69207|2gccst|aConsultations
7101 |aCanada. |bPatented Medicine Prices Review Board.
77508|tDocument d'orientation sur les lignes directrices du CEPMB |w(CaOODSP)9.849045
85640|qPDF|s446 KB|uhttps://publications.gc.ca/collections/collection_2017/cepmb-pmprb/H82-30-2017-eng.pdf